Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond

Figure 5 Improved Overall Survival after combination therapy with molecular targeted agents and immune checkpoint inhibitors[70]. Molecular targeted agents improve survival compared with chemotherapy by cytotoxic agents, but will become resistant sooner or later. Durable long-lasting response is obtained by immune checkpoint inhibitors, but only small portion of patients (15%-20%). Durable long-lasting response will be expected by a combination therapy with molecular targeted agents and immune checkpoint inhibitors in the majority of the patients (50%-70%) with advanced hepatocellular carcinoma.